Adempas (riociguat) / Bayer, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   17 Trials   17 Trials   785 News 


12345678910111213...1415»
  • ||||||||||  Verquvo (vericiguat) / Bayer, Merck (MSD)
    Journal:  Vericiguat: A Promising Drug for the Treatment of Heart Failure. (Pubmed Central) -  Apr 8, 2025   
    Its compatibility with other heart failure therapies without significant drug-drug interactions further highlights its potential as a cornerstone treatment. Ongoing studies continue to explore its benefits, suggesting that vericiguat may enable more comprehensive and effective management of heart failure, reducing the burden of this debilitating condition.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD), Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
    Review, Journal:  Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects. (Pubmed Central) -  Mar 27, 2025   
    The latest addition to treatment options is soluble guanylate cyclase stimulators, such as Riociguat, which directly stimulates the nitric oxide pathway, facilitating vasodilation...Besides prevailing therapies, emerging PH treatments target growth factors and inflammation-modulating pathways, with ongoing trials assessing their long-term benefits and safety. Hence, this review explores current therapies that delay progression and improve survival, as well as future treatments with curative potential.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Retrospective data, Journal:  Effect of balloon pulmonary angioplasty on chronic thromboembolic pulmonary hypertension: an assessment of the learning curve in a Japanese university hospital. (Pubmed Central) -  Mar 16, 2025   
    Specifically, the increase in SaO2 and home oxygen therapy discontinuation rate, and oral riociguat discontinuation rate was significantly higher in cohort 2 (+?7.7, 75, and 59%) compared to cohort 1 (+?3.1, 27, and 10%) (P?<?0.05)...The BPA sessions conducted at the YCUH resulted in significant improvements in patients with CTEPH. This study demonstrates a clear learning curve regarding the effectiveness of BPA both in normalizing SaO2 and facilitating the cessation of home oxygen therapy, as well as in reducing the incidence of severe complications.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Preclinical, Journal:  Effect of Riociguat on Adenine-Induced Chronic Kidney Disease in Rats. (Pubmed Central) -  Feb 26, 2025   
    The renoprotective effect of riociguat is probably due to anti-inflammatory and antioxidant actions. This indicates that riociguat may have the potential to slow the progression of kidney damage in chronic kidney disease (CKD).
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Review, Journal:  MD, Doctor of Medical Science, Head of the Department of Pulmonary Hypertension and Heart Diseases, Myasnikov Clinical Cardiology Institute (Pubmed Central) -  Feb 12, 2025   
    Particular attention is paid to the strategy of therapy optimization in the form of replacing phosphodiesterase type 5 inhibitors with a stimulator of soluble guanylate cyclase (riociguat) in patients with PAH and inoperable/residual CTEPH who cannot not achieve treatment goals on phosphodiesterase type 5 inhibitors. The authors analyzed and identified the criteria justifying the choice of a specific therapy strategy in favor of switching from a phosphodiesterase type 5 inhibitor to riociguat.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD), Opsumit (macitentan) / Nippon Shinyaku, J&J, Tracleer (bosentan) / J&J, Roche
    Journal:  A simple HPLC-UV method for monitoring therapeutic adherence in pulmonary arterial hypertension. (Pubmed Central) -  Feb 2, 2025   
    For RIO, BOS and MAC, the developed method was suitable for both C0 and C3 samples, allowing steady-state drug determination if used. The presented method can be recommended to laboratories equipped with basic HPLC apparatus as an attractive analytical tool for both TDM and adherence studies.
  • ||||||||||  Review, Journal:  Shifting Paradigms in the Management of Pulmonary Hypertension. (Pubmed Central) -  Jan 28, 2025   
    Pulmonary artery denervation and balloon pulmonary angioplasty have emerged as viable alternatives in PH that are resistant to drug therapy. This article aims to summarise the key changes and recent advances in diagnosis and managing PH in general, with an emphasis on certain subgroups.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD), Uptravi (selexipag) / J&J
    CONSIDERATION OF CLOSURE OF A PATENT DUCTUS ARTERIOSUS COMPLICATED BY EISENMENGER SYNDROME - Eric Bailey (Board no. 166; South Hall) -  Jan 27, 2025 - Abstract #ACC2025ACC_4455;    
    Eisenmenger physiology is not an absolute contraindication to PDA closure in the right clinical setting. The shunt in this case reversed evidenced by her recurrent pulmonary edema and significant left-to-right shunting, facilitating the feasibility of this procedure.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD), Uptravi (selexipag) / J&J, Opsumit (macitentan) / Nippon Shinyaku, J&J
    Giant Pulmonary Artery Aneurysm Compressing Left Lung and Pulmonary Drainage (Poster Hall) -  Jan 19, 2025 - Abstract #ISHLT2025ISHLT_285;    
    Palliative medicine was engaged, and she decided to pursue transplant evaluation elsewhere.Summary Giant PAAs carry major implications for transplant surgery and potential need for multiorgan transplant. Secondary PR is often associated with rapid deterioration and timely referral for advanced therapies should be considered in PH patients with giant PAA.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Journal:  Riociguat in pulmonary arterial hypertension: Application of the 4-strata COMPERA 2.0 risk assessment tool in the PATENT studies. (Pubmed Central) -  Jan 6, 2025   
    Efficacy and risk assessment results suggest that riociguat can be beneficial for patients with PAH, irrespective of the presence of comorbidities. In conclusion, this analysis supports the risk-reduction benefits of riociguat in patients with PAH at intermediate-low risk and intermediate-high risk, and externally validated the utility of COMPERA 2.0 in the long-term risk assessment of patients from a clinical trial population.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Review, Journal:  Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus. (Pubmed Central) -  Dec 7, 2024   
    An expert panel of 24 physicians, specialized in cardiology and/or pulmonology with expertise in handling all drugs available for the treatment of PAH participated in the survey. All potential therapeutic options for patients at intermediate risk were explored and analyzed to produce graded consensus statements regarding: the switch from endothelin receptor antagonist (ERA) or phosphodiesterase 5 inhibitor (PDE5i) to another oral drug of the same class; the addition of a drug targeting the prostacyclin pathway administered by different routes; the switch from PDE5i to riociguat.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD), Opsumit (macitentan) / Nippon Shinyaku, J&J
    Trial completion date, Trial primary completion date:  EPIPHANY: Effects of Combination Medical Therapy Followed by BPA on Right Ventricular-PA Coupling and Hemodynamics in CTEPH (clinicaltrials.gov) -  Nov 17, 2024   
    P3,  N=15, Not yet recruiting, 
    We here present a unique management in a patient with right heart failure due to arrhythmogenic right ventricular cardiomyopathy during HeartMate 3 LVAD support. Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Journal:  Analysis of riociguat and desmethyl riociguat by UPLC-MS/MS and its interaction with quercetin. (Pubmed Central) -  Oct 3, 2024   
    The levels of riociguat and M1 in rat plasma were measured using the method developed in this study to evaluate the interactions between riociguat and quercetin in rats. The results revealed that quercetin significantly inhibited riociguat and M1 metabolism with increased systemic exposure.
  • ||||||||||  Review, Journal:  New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review. (Pubmed Central) -  Sep 30, 2024   
    Conversely, udenafil, racecadotril, sotatercept, anastrozole, riociguat, tacrolimus, and ralinepag were found to be safe, well-tolerated, and effective in improving hemodynamic measures and 6-MWDs. This study aims to summarize the developing treatment options currently under clinical trials, highlighting the need for further trials before their application in clinical practice.
  • ||||||||||  Retrospective data, Review, Journal:  Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta-analysis. (Pubmed Central) -  Sep 25, 2024   
    Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual-drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Retrospective data, Review, Journal:  Chronic thromboembolic pulmonary hypertension treatment and sex: Systematic review and meta-analysis. (Pubmed Central) -  Sep 20, 2024   
    PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive. Women and men might show different hemodynamic responses to riociguat or BPA for CTEPH.
  • ||||||||||  Adempas (riociguat) / Bayer, Merck (MSD)
    Trial completion date:  PATENT-CHILD: Riociguat in Children With Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) -  Aug 30, 2024   
    P3,  N=24, Active, not recruiting, 
    The tolerance of nintedanib and pirfenidone is a concern, but most of their AEs are mild and controllable. Trial completion date: Jan 2031 --> Jul 2026